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…there are three core requirements for success in medicine: diligence, to do right, 
and ingenuity. 
Atul Gawande 
Better: A surgeon’s Notes on Performance 
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Introduction 
Nursing homes and elderly people have been a part of my life since I was a child. I 
remember coming to work with my mum and experiencing that adults lived in 
nursing homes and ate ice cream because they lacked teeth, and that there was 
something called adult diapers. Since then I have expanded my insight into their 
world and aquired a fond interest for the elderly.  
The nursing home patients are among the frailest people in our community [1]. They 
have lived long lives and accumulated diseases and conditions over the years. Almost 
everyone has been in contact with numerous physicians and different levels of care. 
Many are sent back and forth between the nursing home, out-of-hour services, and 
the hospital [2]. These factors complicate treatment and can lead to polypharmacy 
[3].  
Polypharmacy is often defined as using five or more drugs. This is rather the norm in 
the nursing homes, given that the average numbers of drugs are seven to eight [4, 5].  
Two of the major groups of prescribed drugs are antihypertensive drugs and 
psychotropic drugs. Research on the effect of these drugs in nursing home patients is 
either lacking or shows conflicting results [6-8]. The appropriateness of 
antihypertensives and psychotropics is therefore often questioned. Multiple 
interventions aiming to optimize prescriptions have been tested. Six recent reviews all 
aimed to investigate which interventions were effective [9-14]. Their conclusion is 
that prescribing could be improved, and there is most support for educational 
approaches. Most of the interventions are complex interventions consisting of 
multiple professions and steps. Complex interventions, and many involved 
professions are factors that are known to affect implementation, and thus the outcome 
of the intervention [15].  
To bring the research forward, we wanted to optimize prescribing by the COSMOS 
approach (Figure 1). The COSMOS study aimed to improve the quality of life for 
nursing home patients in an effectiveness-implementation cluster randomized clinical 
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hybrid trial. Five interventions create the COSMOS acronym; COmmunication, 
Systematic pain assessment and treatment, Medication review, Organization of 
activities, and Safety. During the study, these interventions were implemented in 67 
nursing home units across Norway. The intervention consisted of education of 
nursing home staff, systematic assessment and support regarding barriers and 
promoters, clinical assessment of the patient’s symptoms and function, and 
medication reviews with collegial mentoring. In the medication reviews, we used the 
elements usually available in medication reviews: explicit prescribing criteria, clinical 
tests, diagnoses, medical records, and lab tests. In addition, we had available 
systematic assessment of pain, cognition, neuropsychiatric symptoms (NPS), 
function, and quality of life. As a part of the study, the staff talked with the patients 
and relatives about the diseases, prognosis, and goals of care, and organized 
individualized activities for each patient. These pieces, together with an emphasis on 
documentation and follow-up, could increase safety.  
 
The opportunity to be a part of a trial focusing on many aspects of life for the nursing 
home patients initially brought me into this PhD programme. After four years, I want 
to share a piece of the picture with you. With this thesis, I aim to describe the method 
and implementation of the medication reviews in the COSMOS study and explore 
how to optimize prescribing for two of the major drug groups contributing to 
polypharmacy.  
Figure 1 The COSMOS logo 
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Abbrevations and definitions 
Abbreviations 
ACEI Angiotensin converting enzyme inhibitors 
ARB Angiotensin receptor blockers 
ATC Anatomical Therapeutic Chemical index 
CDR Clinical Dementia Rating scale 
CI Confidence interval 
CMAI Cohen Mansfield Agitation Inventory 
CNPI Checklist of Nonverbal Pain Indicators 
COSMIN COnsensusbased Standards for the selection of health status 
Measurement INstruments 
COSMOS Acronym for the RCT trial in Paper 2 and 3: COmmunication, 
Systematic pain assessment and treatment, Medication review, 
Organization of activities, and Safety 
FAST Functional Assessment Staging Tool 
ICD-10 International Classification of Disease 
ICPC International Classification of Primary Care 
MMSE Mini Mental Status Examination 
MOBID-2 Mobilization-Observation-Behaviour-Intensity-Dementia 2 Pain Scale 
NPI-NH Neuropsychiatric Inventory – Nursing Home version 
NPS Neuropsychiatric symptoms 
PSMS Physical Self Maintenance Scale 
QUALID Quality of Life In late stage Dementia 
RCT Randomized Controlled Trial 
SD Standard deviation 
SEFAS Centre for Elderly and Nursing Home Medicine 
SHELTER Services and Health for Elderly in Long TERm care trial 
START Screening Tool to Alert doctors to the Right Treatment 








Deprescribing Reducing drugs under close monitoring 
Multimorbidity Co-occurrence of multiple diseases 
Nonagenarian Person in his/her nineties 
Octogenarian Person in his/her eighties 
On demand drugs Frugs prescribed by a physician to be given if 
necessary 
Polypharmacy ≥5 drugs used regularly or on demand 
Psychotropic drugs ATC-classes: Antipsychotics, anxiolytics, 
antidepressants, hypnotics, and anti-dementia drugs 




Today’s nursing home patients are old, fragile and suffer from multiple conditions. 
Consequently, they use on average seven different drugs each day. The total burden 
of these factors increases the vulnerability to drug related harm. The most common 
condition affecting nursing home patients is dementia, a disease that often renders the 
patients unable to express the harms and side effects of drugs. For this reason, we 
need to exhibit extra caution to avoid harming the patient. 
Aim 
This thesis aims to explore how to optimize prescribing for Norwegian nursing home 
patients. The focus is on two of the major drug groups contributing to polypharmacy: 
psychotropics and antihypertensives. I will also describe the method and 
implementation of the medication reviews we used in the COSMOS study.  
Method 
The thesis is based on a paper from an epidemiological study of three nursing home 
cohorts (Paper 1), and two papers from the COSMOS study (Paper 2 and 3). All 
patients included are 65 years or older and receive long-term care in Norway.  
Paper 1: A cross-sectional study of 4 793 patients from 129 nursing homes. Using 
ordinal logistic regression, we explored the association between the use of multiple 
psychotropic drugs and neuropsychiatric symptoms, common conditions, function, 
and dementia. 
Paper 2: A study on the development of the medication review process in the 
COSMOS study; an effectiveness-implementation cluster randomized clinical hybrid 
trial. The data is from the intervention group, N=297 patents. We describe the 
implementation by structured feedback on the process, barriers and promoters. Two 
researchers read the feedback, identified, and discussed the main messages.  
Paper 3: A cluster-randomized study using the COMSOS method investigating 
whether cognitive status affected change in number of antihypertensive used, and 
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whether change in antihypertensives affected blood pressure or pulse. Data includes 
all patients using antihypertensives at baseline in the COMSOS study, N=295. The 
intervention group received a medication review with collegial mentoring and 
education in the COSMOS elements. The control group continued practice as usual. 
Mixed model analyses were used to compare the groups and investigate change over 
time for the patients at baseline, month four, and month nine. We used change in 
number of antihypertensive drugs used, systolic and diastolic blood pressure, and 
pulse as outcomes.  
Results 
Paper 1: 73% of the patients used psychotropic drugs and 41% used two or more. 
Antidepressants were used by 39%, 30% used sedatives, 24% used anxiolytics, 20% 
used antipsychotics, and 14% used anti-dementia drugs. There was a strong 
association between neuropsychiatric symptoms and use of multiple drugs. Females, 
younger patients, patients independent in daily living, and patients with a diagnosis of 
dementia also used more psychotropic drugs. 
Paper 2: All intervention units in the COSMOS study conducted medication reviews 
with collegial mentoring during the first four months of the study and 92% of the 
patients received a medication review. Implementation facilitators were improved 
communication and enthusiasm towards the study and education. Barriers were lack 
of time, difficulties in involving the staff and physicians, and ethical dilemmas in 
relations to stopping treatment. 
Paper 3: The patients used on average 9.2 drugs, and 1.6 antihypertensives each. 
Mean blood pressure at baseline was 128/71 mmHg, 9% had high pressure and 5% 
low pressure. Some 32% of the intervention patients had at least one antihypertensive 
reduced between baseline and month four, compared to 10% on the control patients. 
For patients with a reduction in antihypertensive drugs, the systolic pressure rose on 




The use of psychotropic drugs and antihypertensives is extensive among nursing 
home patients. Patients with dementia and neuropsychiatric symptoms receive more 
psychotropics. Dementia does not affect deprescribing of antihypertensives. Clinical 
medication reviews can lead to a reduction of antihypertensive drugs.  
To implement a complex intervention, one needs to involve all staff and set aside 
time to implement the intervention. The implementation can lead to greater 
enthusiasm towards the work and improved communication between staff, 
physicians, patients and relatives.  
Consequences 
There is a need to improve the drug treatment for nursing home patients. By working 
together and using each other’s skills and knowledge, we can reduce the use of drugs 
and focus on the right treatment for the individual patient. This thesis demonstrates a 
method that includes systematic assessment of symptoms and a clinical medication 




Dagens sykehjemspasienter er gamle, skrøpelige. De har mange sykdommer og får i 
gjennomsnitt sju legemidler hver dag. Samlet fører dette til at de er mer utsatt for 
legemiddelrelaterte skader. Den vanligste sykdommen blant sykehjemspasienter er 
demens, en sykdom som ofte gjør pasienten ute av stand til å fortelle om skadene og 
bivirkningene medisinene skaper. Vi må derfor være ekstra forsiktige for å ikke skade 
sykehjemspasientene. 
Mål 
Å undersøke hvordan vi kan forbedre bruken av to av de store legememiddelgruppene 
som bidrar til polyfarmasi; blodtrykksmedisiner og psykofarmaka. Jeg vil også 
beskrive metoden vi brukte i KOSMOS studien. 
Metode 
Alle pasientene i studiene er langtidspasienter i Norge, og er 65 år eller eldre.  
Artikkel 1: En tverssnittstudie av 4793 pasienter som ser på sammenhengen mellom 
bruk av flere psykofarmaka og nevropsykiatriske symptomer, vanlige diagnoser, 
funksjon og demens. Vi brukte ordinal logistisk regresjon for å se på assosiasjoner. 
Artikkel 2: Er en studie som ser på implementeringen av legemiddelgjennomgangen i 
KOSMOS studien, en effektivitets-implementering klyngerandomisert klinisk 
hybridstudie. Vi bruker kun data fra intervensjonsgruppen, n=297. Vi måler og 
beskriver implementeringen ved hjelp av strukturerte tilbakemeldinger på prosessen, 
hemmere og fremmere. Tilbakemeldingene fra personalet ble analysert av to forskere 
for å finne hovedtema. 
Artikkel 3: En klynge-randomisert studie med KOMSOS metoden som undersøkte 
om kognitiv status påvirket endring i blodtrykksmedisiner og om endring i 
antihypertensiva påvirket blodtrykk og puls. Vi inkluderer alle pasientene som stod 
på blodtrykksmedisiner ved studiestart i KOSMOS studien, N=295. 
Intervensjonsgruppen fikk KOSMOS intervensjonen med legemiddelgjennomgang og 
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personalet på avdelingene fikk utdanning innen KOSMOS elementene. 
Kontrollgruppen fortsatte som før. Flernivå og longitudinelle analyser ble brukt for å 
sammenligne gruppene og se på endring over tid for pasientene ved start, fire og ni 
måneder. Vi brukte endring i blodtrykksmedisiner, systolisk og diastolisk blodtrykk, 
samt puls som utfallsmål.  
Resultater 
Artikkel 1 viser at 73 % av pasientene brukte psykofarmaka og 41 % brukte to eller 
flere samtidig. Antidepressiva ble brukt av 39 %, 30 % brukte sovemedisin, 24 % 
angstdempende, 20 % antipsykotika, og 14 % anti-demensmidler. Vi fant en sterk 
sammenheng mellom nevropsykiatriske symptomer og bruk av flere psykofarmaka. 
Kvinnene, de yngre, de med høy funksjon og pasienter med en demensdiagnose i 
journalen brukte også mer psykofarmaka. 
Artikkel 2 viser at alle avdelingene i KOSMOS studien utførte 
legemiddelgjennomganger, og at 92 % av pasientene hadde én 
legemiddelgjennomgang i løpet av de fire første månedene av studien. Entusiasme, 
forbedret kommunikasjon og gleden av å lære ble rapportert som fremmere, mens 
manglende tid, vanskeligheter med å involvere alt personell og legene, og etiske 
dilemmaer rund å avslutte behandling var barrierer.  
Artikkel 3 viser at 295 pasienter brukte blodtrykksmedisiner ved start. Pasientene 
brukte i snitt 9,2 legemidler og 1,6 blodtrykksmedisiner hver. Gjennomsnittlig 
blodtrykk ved baseline var 128/71 mmHg, 9 % hadde høyt blodtrykk og 5 % hadde 
lavt blodtrykk. Blodtrykksmedisiner ble redusert hos 32 % av intervensjonspasientene 
og hos 10% av kontrollpasientene. For pasienter hvor blodtrykksmedisiner ble 
redusert, så vi en økning i systolisk blodtrykk på 14 mmHg ved fire måneder, mens 
ved ni måneder var blodtrykket som ved start.  
Konklusjon 
Det er en utstrakt bruk av psykofarmaka og blodtrykksmedisiner blant 
sykehjemspasienter. Pasienter med demens og nevropsykiatriske symptomer får mest 
psykofarmaka. Kliniske legemiddelgjennomganger førte til en generell reduksjon i 
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forebyggende blodtrykksmedisiner. Det var ingen forskjell i nedtrapping av 
blodtrykksmedisiner om pasienten hadde demens eller om pasienten var kognitivt 
frisk.  
For å få implementert komplekse intervensjoner må vi involvere alle ansatte og sette 
av tid til å implementere intervensjonen. Implementeringen kan føre til økt 
entusiasme for arbeidet og bedret kommunikasjon mellom ansatte, legene, pasientene 
og pårørende.  
Konsekvenser 
Det er et behov for å forbedre foreskrivningen til sykehjemspasientene. Ved å jobbe 
sammen og utnytte hverandres kunnskap og evner, kan vi redusere legemidler og 
fokusere på rett behandling til hver pasient. Denne avhandlingen fremmer en metode 
som inkluderer systematisk kartlegging av symptomer og kliniske 
legemiddelgjennomganger med tverrfaglig arbeid og kollegial støtte. 
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1. Background 
1.1 Norwegian nursing homes 
1.1.1 The nursing home 
The definition of nursing homes varies from country to country. Sandford et al 
provide a fine example of this variation [16]. They polled experts in the field of 
nursing homes in 17 countries and found diversity in definitions ranging from 
“facilities giving extended medical care and rehabilitation” to “a place providing 
room and board”. They also point out that the US definition of nursing homes 
includes advanced facilities, resulting in fewer patients with dementia in their 
cohorts. Despite these differences, most countries define long-term care as nursing 
homes outside the hospital, managing chronic medical conditions and providing 
around-the-clock help with activities of daily living. 
Caring for the oldest old is an increasing challenge as the population is aging and 
more and more people develop dementia [17]. Dementia-related costs are responsible 
for 1.2% of the gross domestic product in high-income countries. Almost 50 million 
people are affected by dementia worldwide. The estimate for Norway is 
approximately 70 000 [18]. The population in Norway is 5 258 317; of these are 
768 000 (14.6%) older than 67 years [19]. There are 31 000 beds in long-term care, 
and 3.2% of the population over 67 years are living in nursing homes. The percentage 
of people over 65 years old living in nursing homes in Europe ranges from 0.8% in 
Lithuania to 20% in Slovenia [20]. In Austria, the United Kingdom and the USA 
around 4% of the people aged 65 and older are in nursing homes 
By law, every Norwegian citizen is entitled to nursing home services if this is deemed 
the only solution to give the patient necessary treatment and proper health and care 
services [21]. The municipalities decide whether the patient qualifies for long-term 
care. Most nursing homes are run by the municipalities. A small minority are run by 
non-profit organizations or commercial companies commissioned by the 
municipalities [22].  
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Long-term care consists of different units. Patients with dementia are known to 
express a high degree of NPS, like agitation, wandering, and psychotic behaviour 
[23]. Patients with dementia need smaller units and specialized care [24]. Specialized 
dementia care units have been around since the 80s, however, what they actually 
provide varies greatly [25]. In Norway, such units are small with four to 12 patients 
and admission requires a diagnosis of dementia [26]. Normal long-term care units do 
not require the patient to have dementia, and have no upper limit of patients per unit. 
The percentage of patients with dementia is high in normal long-term care units as 
well, where 79% of the patients are affected by dementia [27].  
1.1.2 The providers of medical treatment and care 
Physicians 
The difference in service provided is reflected in the availability of physicians. An 
international survey of nursing homes in 30 countries found that only one-third of the 
countries had regular visits by a physician to the institutions [28]. In the USA, 
nursing home physicians are specialists with lengthy experience [29]. In Germany, on 
the other hand, the physicians are general practitioners for individual patients in the 
nursing home, and they have offices outside the nursing home [30]. In Norway, the 
medical care in the nursing homes is typically provided by general practitioners with 
visiting hours in the nursing home. Lately, as the Norwegian nursing homes have 
received more responsibility for patients after discharge from the hospitals, more 
physicians are working full-time in the nursing homes [31]. However, the newly 
discharged patients are often in short-term care, and these units are probably where 
most of the increase in physicians is seen. Until March 2017 there were no 
requirements for physicians working in nursing homes other than a medical degree 
[32]. After this new requirements of having, or being qualified under a specialization 
came in place, the Norwegian Medical Association recommends that physicians 
working in nursing homes should have one hour a week for every three long-term 
care patients, and one hour for every two patients in specialized units for patients 
with dementia [33]. This means that one full-time physician can provide for 60-90 
patients. In Norway, 23% of the beds in nursing homes are for rehabilitation and 
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short-stays [19, 33]. These require one physician per 6 to 20 patients. Table 1.1.1 
describes the situation for physicians in Norwegian nursing homes and the most 
conservative estimates on number of physicians (all short term beds are regular short-
term patients, and no units specialize in dementia). According to these numbers, if we 
follow the standards set by the Norwegian Medical Association, there is a shortage of 
physicians in nursing homes. 
Staff 
Norwegian facilities are staffed by registered nurses, typically one per 10 patients, 
and one licensed practical nurse per seven patients [34]. Pharmacists are rarely 
employed by nursing homes. The nursing home staff’s skills and knowledge varies 
across countries. The UK and USA have seen an increase in the use of advanced 
practical nurses in nursing homes [28]. These nurses are educated to work 
independently and provide more advanced treatment than regular registered nurses. In 
Norway, there is no tradition for use of these advanced nurses. However, in 2011, an 
education of advanced nurses (nurse practitioners) started at the University of Oslo. 
There has been an increasing focus on the relationship between quality of care and 
staffing in nursing homes [35-38]. The publications focus on the numbers of different 
professions and personnel, and do not assess the knowledge and skills of the staff. 
The research has primarily been conducted in the USA, with only one study from 
Norway and one from Italy [35, 38]. A Norwegian group investigated the competence 
of nursing staff working in home care services or nursing homes [39]. A 
questionnaire was answered by 1016 nursing staff, and revealed that the nursing staff 
had competence in key areas of nursing. However, there was a lack of competence in 
Table 1.1.1 Nursing home patients and their physicians in Norway, estimates and actual 
numbers 













Total 40 708 Not applicable 814 570 
Short term 9 303 20 465 Not known 
 long-term 31 405 90 349 Not known 




advanced nursing procedures, palliative nursing, patient observation, and nursing 
documentation. The researchers also found that registered nurses had more 
knowledge than the assistants did, and that nursing home staff had more competence 
than staff in home care services.  
1.2 Patients in nursing homes 
Permanent residency in a nursing home becomes more and more likely as we age; 
11% of octogenarians and 30% of nonagenarians in Norway live in nursing homes 
[40]. The average age for patients in long-term care is 85 years in Europe and 
Norway [4, 41]. The majority of the residents are female and over 80% of patients 
have dementia [27].  
1.2.1 Dementia 
Epidemiology 
The World Health Organization’s International Classification of Diseases version 10 
(ICD-10) classifies dementia as a mental and behavioural disturbance [42]. It is a 
chronic, debilitating disease leading to progressive decline in higher cortical 
functions like memory, thinking, calculation, learning capacity, orientation, 
judgement, and comprehension [42]. Increased mortality is also seen in people with 
dementia, and dementia is one of the leading causes of death in the world [43, 44]. It 
is estimated that median survival after a diagnosis of Alzheimer’s or vascular 
dementia is four to seven years [45].  
A study of 696 patients newly admitted to nursing homes in Norway found that 
16.2% had no dementia [27]. Of the people diagnosed with dementia by the study, 
71% had Alzheimer disease, 8% vascular dementia, 2% mixed dementia, 8% 
frontotemporal dementia, 4% Lewy body dementia, and 7% had other types of 
dementia. While 80%, of the nursing home patients had dementia when examined, 
only 56% of them had dementia as a diagnosis in their medical records [27]. At the 
same time, 6% of the patients not diagnosed with dementia had dementia in their 
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medical records. This suggests that diagnostics of dementia are limited and we need 
to critically appraise the diagnoses in the medical records. 
Stages 
A person suffering from dementia will go through different stages of cognitive 
impairment [46]. The progress is highly individual, however Reisberg (1984) 
described the development of Alzheimer disease as follows: In the early and mild 
stages, the person is still able to take care of herself. She will forget pieces of 
personal history and recent events and have reduced concentration. As the disease 
progresses to moderate dementia she will lose orientation to time, date, and place. 
She will remember the names of her closest relatives, but have difficulties dressing 
according to season and weather. In the severe stages of dementia she will lose the 
ability to go to the toilet, dress herself, and eventually the words will be lost. In end 
stage disease, she will not be able to walk, and swallowing difficulties are common. 
At this stage, she will also normally experience infections [46].  
Neuropsychiatric symptoms 
Dementia is closely connected with NPS, which is a range of different behavioural 
and psychological disturbances such as depression, apathy, hallucination, delusions, 
agitation, disinhibition, and aggression. These symptoms will affect virtually 
everyone with dementia at some point in their disease [47]. The symptoms have 
different prevalence rates during the course of the disease. For instance, depression 
and apathy are especially prevalent in the early stages of disease, while psychotic 
symptoms and aggression become more prevalent as the disease progresses [48]. 
Apathy, disinhibition, and irritability are the most prevalent symptoms in nursing 
home patients, and will affect three out of five patients over a four-year period [47]. 
Apathy and agitated behaviour are also the most persistent symptoms. These 
symptoms are burdensome for the patient and caregivers, and reduce the patient’s 
quality of life [49, 50]. They are also main contributors to nursing home admission 
[51]. 
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1.2.2 Other common conditions and multimorbidity 
Although dementia is the most frequent disease in nursing homes [27], other diseases 
are also commonly seen. The Services and Health for Elderly in Long TERm care 
(SHELTER) study pooled data from 57 nursing homes in Israel and seven European 
countries [5]. They found that the patients had an average of two diagnoses each, with 
cardiovascular diseases on the top of the list: ischemic heart disease affecting 26%, 
stroke 22%, and heart failure 18%. Other frequent diagnoses in nursing home patients 
are diabetes (19% of the patients), and atrial fibrillation (21%) [52]. These diagnoses 
often occur together in the same patient. Each diagnosis in itself might not influence 
the patient too much. However, their co-occurrence, also known as multimorbidity, 
can cause considerable frailty for the patient [1]. Frailty reduces the threshold for 
when the patient becomes dependent on help, and minor illnesses or discomforts can 
result in reduced function.  
Symptoms 
All the diseases affecting the nursing home patients have a potential to cause a wide 
array of symptoms. Common symptoms include urinary incontinence (affecting 80% 
of patients) [53], faecal incontinence (40-67%) [53, 54], pain 30-60% [5, 53, 55], 
falls (9-50%) [5, 53], oedema (25%) [53], constipation (6-23%) [53, 56], dyspnoea 
(13-20%) [5, 53], and dizziness (15%) [5]. People with dementia have reduced ability 
to understand and communicate symptoms [46], and discomfort might be expressed 
as behaviours similar to NPS [57, 58]. Most of these symptoms can be treated or 
alleviated– when identified. An assessment of NPS should aim to clarify whether the 
symptoms the patient is expressing are a sign of progression of the dementia, a sign 
of unmet needs, or are they caused by pain or discomfort [59]. 
Assessment of symptoms 
The most used tests for pain and NPS rely on the patients’ ability to report symptoms 
[60, 61]. Since people with dementia are unable to grasp the content of abstract 
questions relating to feelings and time span, a proxy-rater with sound knowledge of 
the patient has to evaluate the patient [62]. The array of assessment instruments is as 
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varied as a bouquet of spring flowers. For example, there are at least twelve 
instruments used for assessment of pain in people in with dementia. Of these, three 
are translated into Norwegian; DOLOPLUS 2 scale [63], checklist of nonverbal pain 
indicators (CNPI) [64], and Mobilization-Observation-Behaviour-Intensity-Dementia 
(MOBID-2) pain scale [65]. The two former rate pain-related behaviours, while the 
latter rates pain related to active movements. CNPI and MOBID-2 can also be used to 
evaluate the treatment effect of analgesics [65, 66]. MOBID-2 is the only instrument 
available in Norway where pain can be located through five active movements. The 
same diversity of different scales is found for assessment of neuropsychiatric 
symptoms, and quality of life, and no one assessment tool is recommended over the 
others [67, 68]. 
Non-pharmacological treatment of neuropsychiatric symptoms 
When the proper clinical investigations and assessment of NPS is done, we can 
identify, treat, and alleviate the conditions and meet otherwise unmet needs [69]. In 
treating NPS, non-pharmacological approaches should be tested before the initiation 
of drugs [70-73]. There is a wide variety of non-pharmacological interventions tested 
on NPS, ranging from person-cantered care, exercise, music, validation therapy, and 
reminiscence therapy. All these therapies impose a low risk of harm [74], and 
education of staff has the best documentation to improve the residents’ and staffs’ life 
[75].  
1.3 Drugs in nursing homes 
1.3.1 Demographics 
The average nursing home patient use seven to eight drugs every day [5, 76] – as a 
result, the majority of patients are affected by polypharmacy. The most frequently 
administered drugs are laxatives, analgesics, antiulcer drugs, anticoagulants, 
antihypertensives, and psychotropic drugs [5, 76]. Over the past decade, there has 
been a shift towards more analgesic prescriptions, particularly for paracetamol and 
strong opioids [4]. Our research group might have contributed to this by focusing on 
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how pain treatment can alleviate agitation [77]. At the same time, the use of 
psychotropic drugs has increased, especially antidepressants, hypnotics, and 
anxiolytics are surging [78]. Antipsychotics are the only class of psychotropic drugs 
with a reduction in use.  
1.3.2 Psychotropic drugs 
Psychotropic drugs are mostly prescribed for NPS [69]. Antipsychotics are the 
second-line treatment for agitation and psychosis, and studies have shown that these 
symptoms go hand in hand with antipsychotic prescribing [79, 80]. Antipsychotics 
were discredited in the USA in 2005 due to increased mortality risk [81]. Therefore, 
antidepressants and anti-dementia drugs have received increasing attention in 
treatment of NPS [8]. A meta-analysis investigated the effect of psychotropic drugs 
on NPS in patients with Alzheimer disease [82]. The analysis revealed a positive 
effect on total burden of NPS for atypical antipsychotics and cholinesterase inhibitors 
(Table 1.3.1).  
Antidepressants and memantine did not affect NPS. The use of antipsychotics and 
cholinesterase inhibitors led to more dropouts and side effects than antidepressants 
and memantine [82]. The effect of antidepressants on depressive symptoms in people 
with dementia is also debatable [83]. Anti-dementia drugs show significant 
improvement in cognition for people with dementia, meanwhile, these effects are 
minor and the drugs have substantial side effects [84]. Discontinuation studies of 
antidepressants, antipsychotics, cholinesterase inhibitors, and sedatives show that 
these drugs can safely be discontinued under close monitoring [85-88]. 
Table 1.3.1 Effects of psychotropic drugs on NPS in patients with Alzheimer disease, results 
from Wang et al., 2015 
Treatment Standard mean difference 
(95% confidence interval) 
Atypical antipsychotics vs placebo -0.21 (-0.29, -0.12) 
Cholinesterase inhibitors vs placebo -0.12 (-0.23, -0.02) 
Antidepressants vs placebo 0.01 (-0.35, 0.37) 
Mood stabilizers vs placebo 0.96 (0.16, 1.76) 
Memantine vs placebo -0.12 (-0.27, 0.03) 
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Despite the limited effect and considerable adverse-events issues, the use of 
psychotropic drugs is high, with 70% of the nursing home patients using at least one, 
and 22% using a combination of psychotropics [78]. It is also remarkable that patients 
are prescribed these drugs for many years. A study investigated 1163 nursing home 
patients and their psychotropic drug use over time [89]. The residents were assessed 
at baseline, and after 12, 31, 52, and 72 months. Between any two assessments, the 
persistence for any psychotropic drug was over 50%, except for anti-dementia drugs 
where the persistence fell to zero. Change in symptoms between two assessments did 
not affect persistence [89].  
1.3.3 Antihypertensive drugs 
Hypertension is one of the major risk factors for stroke and cardiovascular disease 
[90], and cardiovascular diseases are the top causes of death in the world [44]. 
Treating hypertension significantly reduces the risk of these diseases and death [90]. 
The European guidelines on management of hypertension state that antihypertensive 
treatment is recommended for fit elderly over 80 years if systolic blood pressure is 
160 mmHg or more [90]. For frail elderly, they leave the decision to the treating 
physician based on monitoring and effects of treatment. All of the antihypertensives 
are recommended in the treatment of hypertension; however, diuretics and calcium 
antagonists are preferred in isolated systolic hypertension. The most used drugs with 
antihypertensive effects are diuretics, angiotensin converting enzyme inhibitors 
(ACEI)/angiotensin receptor blockers (ARB), beta-blockers, and calcium channel 
blockers [5].  
The association between treatment and favourable outcomes in the frailest and oldest 
patients is contradictory. The studies investigating the effect of antihypertensives in 
people over 80 have excluded nursing home patients and people with dementia [91, 
92]. A Swedish study on 406 nursing home patients found that low, rather than high 
blood pressure, was associated with increased mortality [52]. Between 7 to 13% of 
the nursing home patients have a systolic pressure above 160 mmHg [52, 93], but 
45% receive antihypertensives [94]. Antihypertensive treatment can cause 
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hypotension. A cross-sectional study of 5066 patients aged 80 years and older treated 
for hypertension; found that 34% had hypotension [95]. The most disturbing result 
from this study was that 59% of the hypotension identified with ambulatory blood 
pressure monitoring was not detected by office measures.  
1.3.4 Why is drug treatment difficult? 
The range of drugs the patient should use according to the disease-specific guidelines 
when he or she have multimorbidity is wide [96]. This can cause polypharmacy, an 
individual risk factor for side effects, inappropriate drug use, and hospitalization [3].  
A main point is that the guidelines are disease specific, and do not address the 
multimorbid nature of the nursing home patients [97]. A second core point is that the 
research on drug effectiveness excludes the elderly and frail [98]. If we do not 
consider these two factors when treating the frail, multimorbid elderly – we can cause 
Figure 1.3.1 Why is prescribing difficult? Factors influencing prescribing and results of 





























serious harm. An overview of factors complicating prescribing is given in Figure 
1.3.1. 
Increased succeptibility to side effects 
Old people, and especially patients suffering from dementia, are more susceptible to 
side effects than younger patients [99, 100]. These side effects include falls, fractures, 
delirium and even death [100-102]. Delirium is an acute change in cognitive status, 
with the hallmarks fluctuation in symptoms and inattention [103]. It increases 
mortality but is preventable in 30-40% of the cases. Predisposing factors for side-
effects are present in the average nursing home patient: dementia, functional 
impairment, multimorbidity, old age, and sensory impairment.  
Phamacokinetic and pharmacodynamic changes 
As the body ages, internal organs and cells alter [104]. These changes lead to 
pharmacokinetic and pharmacodynamic changes. Important pharmacokinetic changes 
are reduced kidney function and altered fat-to-muscle ratio. A reduced kidney 
function leads to excess concentration of drugs or metabolites execrated by the 
kidneys, like the increase seen of the active metabolites of morphine [105]. The 
increase in body fat inflates the volume of distribution for fat-soluble drugs like 
benzodiazepines and escalates their half-life. Pharmacodynamic changes might 
increase or decrease sensitivity to drugs, and cause unpredicted adverse events [104].  
Interactions 
Adverse events can also be caused by drug-drug interactions or drug-disease 
interactions [106]. A drug-drug interaction is an alteration of the effect of one drug 
due to another drug, while a drug-disease interaction is when a drug prescribed for 
one condition exacerbates another pre-existing, chronic condition.  
Known drug-drug interactions can be identified by imputing drugs in interaction 
databases. In Norway the database is readily available in apps and online [107, 108]. 
The database only compares pairs of drugs, and is not capable of estimating the 
effects of a combination of more drugs. Another weakness is the poorer 
representation of pharmacodynamic interactions in the database.  
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Drug-disease interactions require a clinical understanding of the patient and 
pharmacological understanding of the drugs [106]. The risk of interactions increase 
with the number of drugs prescribed, and when a patient receives eight drugs, the 
average number of interaction is one [109].  
1.4 Interventions in nursing homes 
A search on pubmed.gov for clinical trials in nursing homes reveals 2186 trials 
published before January 2016 (Figure 1.4.1). During the past decade there have been 
over 100 published trials concerning nursing homes each year. Dementia care, drug 
use, and infection control are major topics of these studies. The interventions often 
involve multiple professions and several modes of delivery of the intervention [9].  
The complicated nature of nursing home patients makes “one-size-fits-all”-solutions 
hard to design. Therefore, one can either aim a specific intervention at a small 
selected group of patients or create a more general approach for different patients and 
units. The former choice is often tested by randomized controlled trials, the gold 
standards and backbone of evidence based medicine [110]. The latter choice often 
calls for complex interventions. These are interventions with many organizational 
levels involved, multiple different actions, multiple outcomes, and a need for 
Figure 1.4.1 Published articles in pubmed.org on 
clinical trials in nursing homes  
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flexibility in tailoring the intervention [15]. The planning, conductance, and reporting 
are somewhat different between the two types of trials.  
By nature, the complex interventions involve many organizational levels and 
different interventions. The development of this type of study requires identification 
of the existing evidence –regarding both the interventions and how to evaluate them 
[15]. Another aspect is to use the evidence and theory to develop a theoretical 
understanding of what type of change we want, and how change will occur [15]. The 
next step is to develop a model for the intervention process and pilot it. The pilot 
should investigate key parts that might need improvement.  
Conducting complex studies is more flexible than performing traditional randomized 
controlled trials. The flexibility makes it possible for the researchers to adjust the 
intervention towards the needs of the different participants [15]. Scientific reporting 
should therefore be done on all the areas in the process: development, evaluation, 
testing, and implementation. This requires, in addition to the traditional reporting of 
primary endpoints, a sound description of the method, implementation strategies, and 
the extent to which the intervention was implemented.  
These aspects are often lacking, and data on implementation is only reported in five 
of the 14 studies in the review by Forsetlund [12]. The five studies that do report on 
implementation do this to a varying degree. This makes the interpretation of study 
results difficult. We do not know if the intervention succeeded or failed because of 
the (in)effectiveness of the implementation or (in)effectiveness of the interventions. 
Complex interventions are notoriously difficult to implement, and translating the 
evidence from these studies into practice is a slow process [111]. Some of the 
hindrances include lack of economic incentives, lack of staff knowledge, 
understaffing and high turnover rates among staff [111]. 
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1.5 Methods of improving prescribing 
1.5.1 Optimal prescribing 
There are two main approaches for assessment of prescribing in the elderly; using 
explicit criteria or implicit measures that are judgement-based [112]. Some of the 
most used explicit criteria internationally and in Scandinavia are listed in Table 1.5.1 
[113-119]. The table shows that most of the criteria are intended for the general older 
population, not the nursing home population. There is also a huge variability of the 
number of criteria in each list. All, except the PRISCUS list [116], include diagnose 
specific advices as well as general advice on drugs. The explicit criteria have been 
Table 1.5.1 Explicit lists for prescribing to older patients 
Author (year), 
country 




society expert panel 
(2015), US 
Beers Criteria for 
Potentially Inappropriate 
Medication Use in Older 
Adults  
86 Ambulatory, acute, and 
institutionalized settings of 
care for populations aged 65 
and older in the United States, 
with the exception of hospice 






prescribing in older 
people: version 2  
STOPP: 80 
START: 34 
Patients aged 65 and older who 




French consensus panel 
list 
34 French population aged 75 
years and older 
Holt (2010), Germany PRISCUS  30 Elderly patients 
Pazan (2016), 
Germany 
FORTA  240 Elderly patients 
Swedish National 









NORGEP-NH  34 Nursing home patients 
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criticised because they do not take into account co-morbidity or the patient’s wishes 
[112].  
The implicit criteria are judgement-based, and often focus more on the patient than on 
the individual drug – this is an individual process and the outcome will vary between 
physicians [112]. The most used implicit criterion is the Medication Appropriateness 
Index, consisting of 10 questions for every drug prescribed [120]. These 10 questions 
concern indication, correct medication for the indication, dosage, correct direction, 
drug-drug interactions, drug-disease interactions, duplicate drugs, duration, and cost 
of drug. The implicit criteria are time consuming to apply and are demanding for the 
clinician to use [112].  
Two Swedish studies investigate the sensitivity and specificity for the different 
criteria to identify suboptimal prescribing compared to a gold standard in 200 hip 
fracture patients aged 65 and older [121, 122]. The results are presented in Table 
1.5.2 [121, 122]. By sensitivity they meant how many of the patients identified by the 
gold standard as having inappropriate prescribing were also identified by the criteria. 
Specificity was defined as the proportion of patients with appropriate drug treatment 
according to a gold standard, not identified by the criteria. The gold standard was 
Table 1.5.2 Comparison of different indicators to assess prescribing quality in hip-fracture 
patients over 65 years 





Gold standard 71% NA NA 
French consensus panel list 27% 0.33 (0.26-0.41) 0.88 (0.77-0.94) 
PRISCUS 22% 0.29 (0.22-0.37) 0.97 (0.88-0.99) 
Swedish indicators 41% 0.51 (0.43-0.59) 0.83 (0.72-0.91) 
Polypharmacy (≥5 drugs) 75% 0.86 (0.80-0.92) 0.53 (0.41-0.65) 
Excessive polypharmacy 
(≥10 drugs) 
25% 0.32 (0.25-0.40) 0.93 (0.82-0.97) 
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defined as a screening with the START/STOPP criteria [123] and evaluation of the 
identified problems as clinically relevant or not by a geriatrician and a general 
practitioner. One striking aspect is the ability of polypharmacy to detect poor 
prescribing, underlining the connection between polypharmacy and inappropriate 
treatment.  
1.5.2 How to optimize prescribing? 
Combining implicit and explicit criteria can reduce the drawbacks with both 
approaches. This can be done in multidisciplinary medication reviews or case 
conferences. Five recent reviews analyse the effects of interventions aimed at 
improving prescribing in nursing homes (Table 1.5.3) [9-12, 14]. These reviews 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The interventions used by the studies identified in the reviews are listed in Table 
1.5.4. Twenty-one of 39 studies use multicomponent approaches. Education was by 
far the most frequently used intervention. Education was aimed at the staff and/or 
physician, and involved teaching sessions, workshops, education material, or 
combinations of these. The medication reviews in 12 studies were performed by the 
pharmacist, in seven by a multidisciplinary team, and in three by someone other than 
a pharmacist. In ten of the studies where the main prescriber was not involved in the 
medication review, he or she was present in in case conferences. The other studies 
gave written feedback to the main prescriber, without the possibility of discussing the 
cases.  
The main conclusions of the reviews (Table 1.5.3) are that the studies are diverse and 
the effects are minor. However, there is best evidence for the educational approaches 
to improve the quality of prescribing. The ideal mode of delivery or intensity is still 
not known [75]. A review from 2013 on multidisciplinary interventions in nursing 
homes found that interventions involving multidisciplinary team meetings, the 
patient’s physician, and a pharmacist were the most successful [124].  
Deprescribing and person-centered care 
There is an emerging focus on the term deprescribing as a way to optimize 
prescribing for the elderly [125, 126]. There is no clear definition of this term, and 
Table 1.5.4 Interventions used for optimizing prescribing 






Medication review  
Pharmacist 12 
Multidisciplinary 7 
Not multidisciplinary, performed by other profession than pharmacist 3 
Case conferencing 10 




Reeve et al. identified characteristics of definitions across 37 publications [125]. 
These are presented in Table 1.5.5 
Despite the lack of a clear definition, deprescribing is now an accepted term and is 
increasingly used when appropriateness of drugs is considered [125]. Another 
emerging term regarding long-term care is Person-Centred Care. The American 
Geriatric Society tasked an expert panel with defining this term and decided on “(the) 
individual’s values and preferences are elicited, and, once expressed, guide all aspects 
of their health care, supporting their realistic health and life goals” [127]. This is also 
described as a process with clearly defined outcomes, multidisciplinary work and 
continuous education. These two terms go hand in hand and their intent is present in 
most studies focusing on optimizing prescribing. 
1.6 Rationale of the thesis 
From the above paragraphs, we can conclude that to improve prescribing we should 
educate the staff, include the physician and a pharmacist, and use multidisciplinary 
team meetings. To evaluate the patient’s many symptoms and diagnoses we need a 
holistic approach taking all the elements in Figure 1.3.1 into account. This would 
require a complex intervention; hence, the development of the method needs to be 
addressed, as well as the implementation process and the primary outcomes.  
  
Table 1.5.5 Characteristics included in definitions of deprescribing identified by Reeve et al 
(2015) 
Characteristics of deprescribing Number of studies that use the 
characteristic in their definition 
Stop, cease, withdraw, discontinue, remove 35 
 long-term use, potentially inappropriate drugs 18 
Structured, process 13 
Planned, supervised, judicious  11 
Multiple steps 7 
Dose reduction, substitution 7 




2. Aims of the studies 
The aim of this thesis has been to examine how to optimize prescribing for two of the 
major drug groups contributing to polypharmacy: antihypertensives and 
psychotropics. I also wanted to describe the method and implementation of the 
medication reviews in the COSMOS study. This has been achieved by performing 
one cross-sectional study (Paper 1), one method development and implementation 
process evaluation (Paper 2), and one effectiveness-implementation cluster 
randomized clinical hybrid trial (Paper 3), resulting in three papers. Their individual 
aims were: 
Paper 1 
Investigate the use of psychotropic drugs and the patient characteristics associated 
with the use of multiple-psychotropic drugs. 
Paper 2 
Describe a novel implementation strategy for a multidisciplinary medication review 
and report:  
• How did nursing home staff receive the intervention?  
• To what degree was the medication review implemented successfully? 
• What are the barriers and facilitators for implementing multi-disciplinary 
medication reviews in nursing homes? 
Paper 3 
To investigate how a systematic medication review supported by collegial mentoring 
affected the use of antihypertensives. Secondary objectives were to assess 
associations between blood pressure at baseline and changes in antihypertensive 
drugs, and describe the effects of changes in therapy on blood pressure after four and 
nine months.  
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3. Methods 
3.1 Overview of the papers 
All papers included only patients living in Norwegian long-term care units. We 
recruited the units first, and then all the patients in the units were screened for 
eligibility. Patients had to be 65 years or older, and have stayed in the unit for at least 
two weeks before first assessment. Dying patients were excluded. Registered nurses 
in the units used validated instruments for people with dementia to obtain data on 
clinical and psychological status. The patient’s records provided information on 
prescribed drugs, diagnoses, and demographics. An overview of design, number of 
patients, inclusion, and exclusion criteria is shown in Table 4.1.1. Paper 1 is based on 
data that was collected from 2004-2011 [128-130]. Papers 2 and 3 are based on the 
COSMOS study.  
Table 4.1.1 Overview of papers 
Paper Design (study) Inclusion and exclusion criteria Number of 
patients 
1 Cross-sectional (Selbaek 
2007, Kirkevold 2009, 
Helvik 2015) 
Inclusion 
• At least a two-week stay in long-
term care 








• At least a two-week stay in long-
term care 
• ≥65 years 
Exclusion 
• Dying 
• Control group patients 




randomized clinical hybrid 
trial (COSMOS) 
Inclusion 
• At least a two-week stay in long-
term care 
• ≥65 years 
• Use of antihypertensives at baseline 
Exclusion 
• Dying 




3.1.1 Assessment instruments used in the papers 
People with dementia have reduced abilities to express pain and discomfort. They are 
reliant upon evaluation from others to be treated correctly. In the papers, we used a 
number of instruments validated for people with dementia. Only nurses having daily 
contact with the patients answered the instruments. All nurses received at least four 
hours of training before using the instruments. The researchers performed all the Mini 
Mental Status examination (MMSE). The following section contains a short 
description of the instruments used in the papers and Table 3.1.2 indicates how the 
instruments were used in the individual papers.  
Cognition 
Mini Mental Status Examination – MMSE 
MMESE tests cognitive function by asking the patient 30 questions in the domains of 
orientation to time, orientation to place, registration, attention and calculation, recall, 
language, repetition, and complex commands [131, 132]. The answers are scored 
correct (1) or wrong (0), range 0–30. Lower scores indicate lower cognitive function. 
Normal cognition was defined as 26–30, mild dementia: 21–25, moderate dementia 
11–20, severe dementia <11 [133].  
Table 3.1.2 Overview of the use of instruments in the papers 
Instrument Paper 1 Paper 2 Paper 3 
MMSE  D, MR D, P, MR 
FAST  D, MR MR 
CDR D, P   
NPI-NH total 
 
D, P1 D, MR2 MR2 
NPI-NH psychosis: Delusions and hallucination P   
NPI-NH affective symptoms: Depression and anxiety P   
NPI-NH agitation: agitation and irritability P   
CMAI  D, MR MR 
Cornell  D, MR MR 
MOBID-2  D, MR MR 
PSMS D, P MR MR 
QUALID  MR MR 
D: used in the demographic section, MR: instrument used in medication reviews, P: Predictor 
1Includes the 10 items: Delusions, hallucination, agitation, depression, anxiety, euphoria, 
apathy, disinhibition, irritability, and aberrant motor behaviour. 2Includes the 12 items: 
Delusions, hallucination, agitation, depression, anxiety, euphoria, apathy, disinhibition, 




Functional Assessment Staging – FAST 
FAST stages cognitive function from normal to severe dementia [134]. Functioning is 
divided into seven major levels. A nurse marks the level that best fits the patient’s 
functional status. Normal cognition was scored as 1–2, mild dementia as 3–4, 
moderate dementia as 5, and severe dementia as 6–7. The instrument has good 
validity and reliability [135]. 
Clinical Dementia Rating scale - CDR 
CDR rates cognitive function from normal to severe dementia [136]. The test covers 
the domains memory, orientation, judgment and problem solving, community affairs, 
home and hobbies, and personal care. The score goes 0 to 3, 0: no cognitive 
impairment, 0.5 questionable cognitive impairment, 1: mild dementia, 2: moderate 
dementia, 3: severe dementia. It is reliable and valid in diagnosing dementia [136-
138]. 
Neuropsychiatric symptoms 
Neuropsychiatric Inventory- nursing home version – NPI-NH 
NPI-NH assesses neuropsychiatric symptoms in the twelve domains delusions, 
hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, 
irritability, aberrant motor behaviours, night-time behaviours, and eating disturbances 
[139]. Each domain is scored on frequency (absent to daily; 0–4), and intensity for 
the patient (mild to severe; 1–3). These scores are multiplied to a sum score of 0–12 
for each item. The NPI-total is a sum of the scores for each domain. It has good 
validity and reliability [140].  
Paper 1 only uses the first 10 domains in the sum score, excluding nighttime 
behaviours and appetite since these items were added to the instrument at a later time. 
As such, the maximum score is 120. Paper 1 also uses sub-syndromes constructed 
from a factorial analysis of the NPI-NH scale [141]. In these, two and two domains 
are joined to create sub-syndromes: agitation (agitation and irritability), affective 
symptoms (depression and anxiety), and psychosis (hallucinations and delusions) 
[141].  
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Papers 2 and 3 use all twelve domains when calculating the sum score. Paper 2 also 
uses a cut-off score of four or more on an individual item as a clinically significant 
symptom. 
Cohen-Mansfield Agitation Inventory – CMAI 
CMAI investigates 29 agitated behaviours in the domains aggressive behaviours, 
physical non-aggressive behaviours, verbally agitated behaviours, and hiding and 
hoarding [142]. The items are scored on frequency (never to multiple times an hour; 
1–7), sum score range: 29–203. In Paper 2, agitation was defined as a score of 39 or 
more. The instrument is reliable and valid to assess agitation in nursing home patients 
[142].  
Cornell Scale for Depression in Dementia – Cornell 
Cornell assesses depression through 18 questions in the domains mood, behavioural 
disturbances, physical signs, cyclic function, and ideational disturbances [62]. The 
items are scored absent to severe (0–2) and summed to give a sum score with a range 
from 0 to 38. In Paper 2, depression was defined as ≥8. Cornell is reliable and valid 
for assessing depression among institutionalized patients with and without dementia 
[143].  
Other assessment instruments 
Mobilization-Observation-Behaviour-Intensity-Dementia Pain Scale - MOBID-2  
MOBID-2 measures pain intensity in five standardized, guided movements, and in 
five domains related to internal organs, head and skin in the last week [144]. Each 
item is scored from 0 to 10 (no pain to worst imaginable pain). A total pain score is 
based on the worst pain experienced in the 10 domains, ≥3 signifies a need for pain 
treatment. The instrument has good validity and reliability for assessing pain in 
people with dementia; it is also responsive to detect change in pain after adjusting 
treatment [65]. 
Physical Self-Maintenance Scale – PSMS 
PSMS assesses personal activities of daily living in the areas toileting, feeding, 
dressing, grooming, physical ambulation, and showering [145]. The items are scored 
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based on whether the patients are able or unable to do the activity (0-5). A higher 
score signifies more dependency. It has good reliability and validity for assessing 
function in older people [145].  
Quality of Life In Late-stage Dementia – QUALID 
QUALID assesses quality of life with 11 questions about to what extent the person 
smiles, appears sad, cries, has facial expression of discomfort, appears physically 
uncomfortable, verbalizes in a way that suggests discomfort, is irritable or aggressive, 
enjoys eating, enjoys touching/being touched, enjoys interacting with others, and 
appears calm and comfortable [146]. Each item is scored from 1 to 5. Lower score 
indicates higher quality of life. QUALID is a reliable and valid tool to measure 
quality of life in people with dementia [147].  
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3.2 Paper 1 
3.2.1 Participants 
This study included three nursing home cohorts from 2004 [128], 2007 [129], and 
2011 [130], including altogether 129 nursing homes throughout the country. Table 
3.2.1 gives an overview of the included cohorts.  
3.2.2 Outcome and analyses 
The outcome in Paper 1 was use the of psychotropic drugs. Psychotropic drugs were 
defined as antipsychotics (N05A), anxiolytics (N05B), sedatives (N05C), 
antidepressants (N06A), and anti-dementia drugs (N06D) according to the 
Anatomical Therapeutic Chemical Index (ATC) classes [148]. The term psychotropic 
drugs is not uniformly defined across articles, partly due to different classification 
systems of drugs across countries, the introduction of new drugs (like cholinesterase 
inhibitors), and differences in outcomes investigated. As we wanted to investigate the 
relationship between psychotropic drugs, dementia, and NPS, drugs treating these 
conditions were included.  
The use of three or more psychotropics in elderly has been defined as inappropriate 
by Swedish and Norwegian prescribing criteria [149, 150]. The patients were 
therefore divided into four groups according to how many regular psychotropic 
prescriptions they used; zero, one, two, and three or more.  
Table 3.2.1 Overview of the three cohorts in Study 1 
Cohort Aim Nursing homes Patients 
2004 Investigate the relationship between 
neuropsychiatric symptoms and 
psychotropic drug use at different stages 
of dementia 
26 NH from 18 
municipalities 
1137 
2007 Examine the practice of concealing 
drugs in food and beverages 
63 NH from south 
eastern Norway 
1879 
2011 Follow-up of the 2004 investigation 63 NH 1723 
NH: Nursing home 
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The ordinal nature of the outcome made it necessary to use ordinal logistic regression 
when investigating associations. As explanatory variables, we used the patient-related 
factors thought to have the greatest influence on psychotropic drug use: cognitive 
status, degree of neuropsychiatric symptoms, polypharmacy, and other diagnoses. 
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3.3 Paper 2 
Paper 2 uses data from the COMSOS trial [151]. COSMOS was a four-month cluster 
randomized implementation-effectiveness clinical hybrid trial (Figure 3.2.1). The 
main aim was to improve quality of life for the patients and reduce NPS. The trial 
was complex with 67 nursing home units, five different interventions, and multiple 
meetings between the researchers, staff, and patients. The nursing home units came 
from seven municipalities in Norway: Askøy, Bergen, Bærum, Kvam, Sarpsborg, 
Sund, and Øygarden. 
I joined the study just when ethical approval was received. The research team 
consisted of project manager Bettina S Husebø (BSH), postdoctoral fellow Elisabeth 
Flo and Irene Aasmul (IA) and I as PhD candidates. Together we recruited nursing 
homes, designed and finished the educational material, and finalized the intervention. 
We piloted the intervention with four small municipalities and subsequently refined 
the data collection method and medication reviews based on pilot experiences.  
The main study was executed in Eastern and Western Norway. IA and I, together 
with two medical students (Torstein Habiger and Tony Elvegaard), collected all the 
data and performed the routine follow-up of all the units including phone calls to the 
units every second week in the first four months of the study. I organized the 
medication reviews with the intervention units, and BSH and I participated in them 
together with the physician and staff from the units. IA and I also planned the 
midway seminars, and I led two out of five of these sessions.  
The study is described in detail in the published protocol [151]. This section will give 
an overview of the five COSMOS elements.  
The complex design with five interventions and all personnel involved in patients’ 
treatment was chosen as single-item interventions and has displayed minor effects 
(Table 1.5.3). The goal was that interventions would reinforce each other.  
Each nursing home patient lives together with other patients in a unit. The patients in 
one unit are served by the same staff and physician. Since the intervention was given 
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to the nurses and physicians, it was reasonable to believe that the change in one 
patient was not independent of the other patients in the unit [77]. This dependency 
requires a randomization of the units (clusters) [152]. The clustered nature of the 
patients also requires statistical analyses taking into account that the observations are 
not independent. The measures were also repeated over time, which also has to be 
considered when choosing statistical methods. This is covered by using hierarchical 




Figure 3.3.1 Flow chart of the COSMOS study and description of the populations 
involved in Papers 2 and 3 
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The interventions 
The COSMOS trial tested a complex intervention consisting of five subsets of 
interventions. The reasoning was that each single intervention is dependent upon the 
other interventions to have maximum effect. It is not ideal to perform medication 
reviews without knowing what the patient and relatives want and believe. Removing 
drugs without a plan for following up the changes, especially removing psychotropics 
without giving proper individualized activities may increase suffering. To assess 
whether the pain treatment the patients received is adequate we need a valid measure 
of pain. To give individualized activities and set the right treatment level, it is 
essential to talk with the patient and relative about their beliefs and wishes. So, even 
though the two included papers from the COSMOS trial focus on medication reviews 
and drug use, the results are dependent on the whole COSMOS intervention.  
Communication 
In the communication section, the focus was on Advance Care Planning. This is a 
continuous process of communication and decision-making with the patient and 
relatives, where we address the patient’s health and approaching death. Practical 
challenges in levels of care and ethics are considered and discussed before the patient 
becomes critically ill [154]. The nurses in the unit were supposed to have these 
conversations with the patient and relatives at least quarterly, and involve the 
physician when necessary.  
Systematic pain assessment and treatment 
In this section, we trained the staff in using MOBID-2 as a tool to detect and follow 
pain in their patients. By using a validated tool for people with dementia, they were 
able to detect over- and under-treatment. The body map on the MOBID-2 also 
visualized where the pain was, and enabled specific measures to reduce this pain. For 
instance, we found a patient in pain when lying on the left side and the left side was 
facing the wall when the patient was in bed. A morning routine involving washing 
and dressing the patient in bed would be better for the patient if the right side faced 
the wall. The staff and physicians were also trained in the Stepwise Protocol to Treat 
Pain [55] to optimize pain treatment. The goal was to assess all patients using 
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MOBID-2 at least two times a year, if the patient’s behaviours changed, before 
initiation of pain treatment, 2–4 days after initiation, and after 8–12 weeks of 
treatment. 
Medication review 
In this section, we trained the nurses to assess the patients for pain, cognitive 
function, and neuropsychiatric symptoms. The staff and physicians received training 
on effects and side effects of drugs and how to assess effectiveness. We implemented 
multidisciplinary medication reviews with collegial mentoring. The physician and 
nurses from the unit participated together with the researchers (BSH and CG). We 
used the information from the assessments, medical records, lab tests, and clinical 
assessment. To support decisions the START/STOPP 2 [114], an online interaction 
database [107], the Norwegian Medicines Agency’s checklist for medication reviews 
[155], and a list of anticholinergic drugs adapted from Duran et al [156] were used. 
The patients were to have a medication review twice a year, if their medical condition 
changed or if they were discharged from the hospital. 
Organization of activities  
By law, all Norwegian nursing home patients are entitled to have individualized 
activities [26]. This is because activities can increase quality of life, improve mood 
and reduce NPS. Activities should always be considered before initiation of 
psychotropic drugs and must be adapted to the patient’s individual interests and 
abilities. The nursing home staff were taught the importance of activities, and given 
tools to map the individual activities for each patient based on preferences, interests, 
and physical and cognitive capabilities. The goal was for each patient to have an 
individual plan of activities with at least 1.5 hours a week of activities. If the patient 
received 1.5 hours a week at the start of the study, we aimed to increase the activities 
by 20%. 
Safety 
This is an overarching theme of the study. The elements in COSMOS are basic 
elements that should be covered for every nursing home patient. By using a system 
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that ensures that the focus is on these areas every fourth week, and document the 
measures, we enhance safety for the patient.  
3.3.2 Participants  
We included 36 intervention units with 297 patients. We also evaluated the COSMOS 
ambassadors (N=73) and physicians (N=21) responsible for the patients.  
3.3.3 Outcomes and evaluations 
The intervention process 
This paper aimed to describe the intervention process. The method section of this 
paper was therefore extensive and resulted in the figure developed in the paper 
(Figure 6.3.1).  
Evaluation of the implementation 
We assessed the degree of implementation by using a log of activities for each 
patient. We asked five questions every fourth week through first four months of the 
study. The questions were: 
• Has the patient had at least one medication review? 
• Are there indications on each drug? 
• Has the patient and/or relative been informed about change? 
• Have any drugs been reinstated after pause? 
• Are changes in patient health documented? 
The barriers and promoters relative to implementation came from the midway 
seminar feedback, open-ended questions at each time-point in the patient logs, and 
feedback during the medication reviews. The feedback was read through by two 
researchers individually and “main messages” were identified. These were compared 
and discussed with all the researchers until consensus was reached.  
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3.4 Paper 3 
3.4.1 Participants 
We included the 227 patients from 35 units using antihypertensive drugs at baseline. 
The antihypertensive drugs were defined as the five most used groups with 
hypertension as a major indication in the Anatomical Therapeutic Chemical Index 
(ATC) [148]. These groups were high ceiling diuretics, beta-blockers, plain 
angiotensin II antagonists, plain angiotensin-converting-enzyme inhibitors, and 
calcium channel blockers with mainly vascular effect. Diagnoses were coded 
according to the International Classification of Primary Care (ICPC). 
3.4.2 Outcomes and analyses 
The primary outcome variable was the use of antihypertensive drugs defined as the 
number of antihypertensives the patients used at each time point. We considered the 
number of drugs used to be a better outcome than use/non-use, since some patients 
used more than one, and reductions or increases would be assessed in this approach. 
Pulse, along with systolic and diastolic blood pressure, was used to see how 
deprescribing affected these measures. Deprescribing was defined as using more 
antihypertensives at baseline than at month four. We did not continuously track 
changes in drug use; instead, we relied on drug use at three time points: baseline, 
month four, and month nine. Most changes appeared between baseline and month 
four. This is where the active intervention occurred, and hence is the period of major 
interest.  
As the use of antihypertensive drugs is a count variable, a Poisson regression was 
appropriate [157]. For the continuous outcomes pulse, systolic, and diastolic blood 
pressure we used a linear regression [153]. The change over time in antihypertensive 
use was different in the intervention and control group, so the analyses investigating 
the association of high vs low/normal blood pressure and cognitive status were 
stratified on group allocation. Deprescribing of antihypertensives was rare in the 
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control group, so we did not investigate the effect of deprescribing on blood pressure 
and pulse in the control group.  
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4. Ethics and approvals 
All studies had the approval of the regional ethics committees before initiation of the 
studies. Paper 1 also had approval from the Norwegian Data Protection Authority and 
the Directorate for Health and Social Affairs. The COSMOS study was registered in 
clinicaltrials.gov. All the registrations, approval numbers and references are listed in 
the papers. 
The inclusion period for the patients in my papers stretched from 2004 to 2015. 
During that time, the Norwegian law regarding requirement of informed consent has 
changed. This is reflected in the different approaches to obtain consent: For the 2004 
cohort in Paper 1, a written informed consent was not required, but the patients were 
informed that they could withdraw from the study. For the 2007 and 2011 cohort and 
for the COSMOS study, a written informed consent was required for participation.  
Written informed consent is a prerequisite when doing research involving humans 
[158]. A person must be informed about “aims, methods, sources of funding, any 
possible conflicts of interest, institutional affiliations of the researcher, the anticipated 
benefits and potential risks of the study and the discomfort it may entail, post-study 
provisions and any other relevant aspects of the study. The potential subject must be 
informed of the right to refuse to participate in the study or to withdraw consent to 
participate at any time without reprisal.” [158]. Patients with moderate to severe 
stages of dementia are often unable to grasp abstract aspects and understand 
consequences of their choices [159]. For this reason people with dementia, are 
generally excluded from trials testing effectiveness of drugs [98].  
The Declaration of Helsinki clearly states that underrepresented groups should gain 
access to taking part in research [158]. It also states that one should provide special 
care when doing research on vulnerable groups, and informed consent is the rule. 
However, for patients lacking the ability to understand an informed consent, a legal 
guardian can accept participation on behalf of the patient. This requires a special 
focus on “do no harm” and that the research could not be done on patients unable to 
consent. 
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The first paper collected data about the patients. Still, the patients were not involved 
in data collection and they were not interviewed. This ensured minimal burden on the 
patient, while they were still contributing to research concerning their daily life.  
The COSMOS study used five well-known and tested interventions in nursing home 
patients; the novelty was to test these together to try to improve the quality of life for 
the patient. If effective, this would have an immediate benefit for the patient. At the 
same time, the interventions posed a minimal risk, as they have already been tested 
individually [151].  
To collect consent in the COSMOS study, we approached all units in the nursing 
homes with information about the study. The information was distributed to the staff 
and patients. In addition, we sent a letter with information about the study to the next 
of kin of the nursing home patients. The patients’ capacity to give informed consent 
was judged by the researchers in a direct talk with the patient. The talk consisted of 
oral and written information about the study and an MMSE test. If the patient was 
deemed capable of signing the consent form, a written consent was obtained if the 
patient wished to join the study. All the next of kin were called and informed about 
the study regardless of the patient’s cognitive status. If the patient was not capable of 
signing an informed consent, the next of kin was asked to sign a presumed consent on 
behalf of the patient. The patient, next of kin, and nursing home staff were informed 
that the patient could withdraw from the study at any time without giving a reason.  
By ensuring that the trials had the proper approvals and were registered in the online 
database before initiations, we also ensured that the trials had a clear plan of 
recruitment, dissemination of the study, a priori hypotheses, and a plan for reporting 
results, thus increasing the transparency of the trials [158].  
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5. Results 
5.1 Paper 1 
Gulla C, Selbaek G, Flo E, Kjome R, Kirkevold O, Husebo BS. Multi-psychotropic 
drug prescription and the association to neuropsychiatric symptoms in three 
Norwegian nursing home cohorts between 2004 and 2011. BMC Geriatr. 
2016;16:115. 
Main findings: 
• Included 4739 patients from 129 nursing homes 
• The patients used an average of 6.6 drugs and 80% had dementia 
• 73% used psychotropics; 32% one, 24% two, and 17% used three or more. 
Range: 0–7 
• 39% used antidepressants, 30 % used sedatives, 24% used anxiolytics, 20% 
used antipsychotics, and 14% used anti-dementia drugs 
• A high degree of NPS was most strongly associated with use of multiple 
psychotropics (OR 1.02, 95 % CI 1.02–1.03). Mean NPI-NH for patients not 
using psychotropics were13.5 (SD 16.3), while for patients using ≥3 
psychotropics it was 25.5 (SD 21.8)  
• This association was especially strong for depressive symptoms (OR 1.10, 
95% CI: 1.09–1.12), where mean NPI-NH was 1.8 (SD 3.5) for patients using 
none, and 3.9 (5.2) for patients using ≥3  
• The women, the younger patients, the patients more independent in daily 
living, and those with a recorded diagnosis of dementia were more likely to 
receive more psychotropics 
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5.2 Paper 2  
Gulla C, Flo E, Kjome R, Husebo BS. Implementation of collegial mentoring and 
systematic clinical evaluation in nursing home patients in a cluster randomized 
effectiveness-implementation clinical hybrid trial: Introducing a novel strategy for 
multidisciplinary medication review. Submitted 2017. 
Main findings: 
• Included 297 intervention group patients in 36 units 
• The patients used on average 7.6 (SD 3.8, range: 0–19) drugs and had 4.4 (SD 
3.3) diagnoses 
• The most prescribed drug groups were laxatives used by 172 (58%) patients, 
antithrombotics 155 (52%), and paracetamol 136 (46%)  
• All units sent the required two participants to the COSMOS education 
program. Of these 61% were registered nurses, 12% licensed practical nurses, 
and 27% of unknown education. Seven (33%) of the physicians participated 
• 13 (62%) of the physicians had a specialty, 12 of which were in family 
medicine, one in internal medicine 
• 55% of the units had the majority of the staff hired for part-time positions 
• The physicians attended for averagely 22 patients (range: 8–28) of the patients 
in the study 
• 33 (11%) patients died during the study 
• All the units endorsed the medication review intervention, and 92% of the 
patients received a medication review during the first four months of the study 
• Facilitators towards implementation were the enthusiasm the intervention 
created and improved communication between all the involved parties 
• Barriers were lack of time, difficulties in involving the staff and physicians, 
and ethical dilemmas concerning prescribing 
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5.3 Paper 3 
Gulla C, Flo E, Kjome R, Husebo BS. Deprescribing antihypertensive treatment in 
nursing home patients and the effect on blood pressure. J Geriatr Cardiol.  Accepted. 
Main findings: 
• Included 164 intervention patients, and 131 control patients, using 9.2 drugs on 
average 
• 43% of the patients had a diagnosis of hypertension, 79% had a cardiovascular 
diagnosis, hence 21% had no cardiovascular diagnosis 
• The other frequent cardiovascular diagnoses were: atrial fibrillation (23%), 
heart failure (17%), and stroke (16%)  
• Mean blood pressure at baseline was 128/71 mmHg, 9% had a systolic 
pressure ≥160 mmHg and 5% a systolic pressure <100 mmHg 
• The average number of antihypertensives were 1.6 
• Between baseline and month four there were 19 (12%) mortalities in the 
intervention group, and 17 (13%) in the control group. Between month four 
and nine 17 (12%) died in the intervention group, and 12 (11%) in the control 
group 
• Between baseline and month four, seven (5%) were hospitalized in the 
intervention group, and 14 (13%) in the control group. Between month four 
and nine, seven (6%) were hospitalized in the intervention group, and 12 
(13%) in the control group. The hospitalization rates were higher for the 
control group at both time points (p=0.031 and p=0.041) 
• Significantly more drugs were reduced in the intervention group. A reduction 
was seen among 32% of the intervention patients and 10% in the control group 
(Incidence Rate Ratio: 0.8, 95% confidence interval: 0.7-0.9) 
• For patients with a reduction in an antihypertensives, the systolic pressure rose 
on average 14 mmHg from baseline to month four, but had decreased to 
baseline levels by month nine 
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6. Discussion 
6.1 General considerations 
In this thesis, I wanted to examine how to optimize prescribing for two major 
contributors to polypharmacy: cardiovascular drugs and psychotropic drugs. The 
focus has been on long-term care patients over 65 years of age. To improve 
prescribing, one needs to know the nursing home setting and the patients; these 
factors are investigated in papers 1 and 2. Papers 2 and 3 describes the development 
of the method for systematic medication review and reports on the effects. The 
following discussion will highlight important aspects when doing research on people 
with dementia and when performing such research in nursing homes.  
When discussing the individual papers, I will focus on how the strengths and 
limitations are related to internal and external validity. Internal validity is the extent 
to which the results are true for the setting in which and the population for whom the 
study was conducted. The external validity refers to how results can be generalized 
the results to other settings and populations [160]. 
6.2 Considerations on study types 
Paper 1 examines the relationship between multi-psychotropic drug use and patient 
characteristics. Paper 1 uses a cross-sectional sample, even though the cohorts were 
from different years. Another way these data could have been analysed is to look for 
time-trends in the prescribing and correlations, and then describing development over 
time. Time trends in use have been mapped in Norwegian samples [78], and our data 
showed consistent associations over time. Cross-sectional investigations of 
associations have also been performed before [128, 161-163]. All these studies 
demonstrate a high correlation between NPS and psychotropic drug use; some also 
report on multi-use. However, none of these studies has focused on whether there is 
an association between more severe NPS and the use of more psychotropics. This 
could only be done in a large cross-sectional study.  
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Papers 2 and 3 are both based on the COSMOS study. A complex design was 
required for the COSMOS study because of the involvement of many different 
professions and interventions [15]. The design entailing five interventions was chosen 
due to the lack of proven effect on quality of life from previous studies that 
investigate single item interventions [9]. The project leader (BS) had also experienced 
in earlier studies [77] that the staff asked for a broader approach incorporating more 
aspects of the patient’s real life in the nursing home. The goal was that interventions 
would reinforce each other. Complex interventions are common when investigating 
nursing home patients, and 53% of the studies involved in the reviews listed in Table 
1.5.3 are complex.  
The COSMOS study was also a hybrid study, which means that we could assess the 
implementation and effectiveness of the intervention in the same study [164]. This 
design is ideal for complex interventions. To reduce the barriers against 
implementation, we needed a study we could adapt to the local setting.  
The COMSOS study was a single blinded study. In our case, this means that the 
patients were not informed which group they belonged to. Only a minority of the 
patients had cognitive capacity to understand that they were part of the study. None 
of the primary outcomes in Paper 2 or 3 include direct answers from the patients; 
hence, the patients knowledge about group allocation would not affect the results. We 
did not blind the participating staff or researchers. The reasoning behind this was that 
the assessment could only be done by staff with knowledge about the patient, and an 
important goal in the COSMOS study was to involve all staff in the units. Hence, 
staff performing the intervention could not be blinded to group allocation.  
The intervention consisted of training, education, medication reviews, and close 
follow-up. This was performed by the research team. This team was also responsible 
for data collection, and was therefore aware of group allocation. 
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6.3 Discussion of the methods 
6.3.1 Paper 1 
Internal validity 
By including three cohorts of Norwegian nursing home patients over a period of eight 
years, and with over 4 000 patients, we could ensure a high internal validity by a 
good representation of Norwegian nursing home patients. The patients in all three 
cohorts were assessed following the same procedure, which increases the strength of 
the findings. A limitation is the difference in obtaining consent over the years; this 
resulted in a lower recruitment rate in the two latter cohorts. We have no comparison 
between excluded and included patients, and cannot say whether this affected the 
results.  
We compared the cohorts, and we found that the 2004 cohort consisted of slightly 
younger patients, who used fewer drugs. This is in line with what we would expect, 
since the average age of nursing home patients has increased and the use of drugs is 
rising [40, 78]. The 2004 cohort was placed between the 2007 and 2011 cohort 
regarding level of NPS, dependency, and cognitive function. Hence, the difference in 
recruitment does not seem to have affected the cohorts to any noteworthy extent.  
Assessment of people with dementia 
When assessing people with dementia, proxy rating of symptoms is essential because 
the patients are often unable to report these symptoms themselves [62].  
An important aspect to consider when choosing which instruments to use is the 
quality of the instruments. The Consensus-based Standards for the selection of health 
status Measurement INstruments (COSMIN) checklist was developed to assure the 
quality of health status instruments [165]. An expert panel went through a Delphi 
process where they first decided on the taxonomy for measurement properties, and 
found three overarching domains: reliability, validity, and responsiveness. The panel 
reached the following definitions [165]: 
Reliability: The degree to which the measurement is free from measurement error. 
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Validity: The degree to which an instrument measures the construct(s) it supposed to 
measure. 
Responsiveness: The ability of an instrument to detect change over time in the 
construct to be measured. 
The expert panel then constructed a checklist for evaluation of studies evaluating 
instruments [166]. All the instruments used in this paper have a high quality 
according to the COSMIN criteria. The instruments are widely used in both clinical 
practice and research, and are readily available online in Norwegian. This makes the 
results easier to compare with other cohorts and between countries.  
External validity 
The sample constitutes an unselected group of nursing home patients from all types 
of units and from the greater part of Norway. It is reasonable to assume that these 
results are representative for most nursing homes in Norway and comparable 
countries.  
In the two latter cohorts, the main cause of exclusion was lack of obtained consent, 
most often because the next of kin failed to provide consent on behalf of the patients. 
To consider consent is especially important when doing research on people with 
dementia, as this group has routinely been excluded from studies due to lack of 
ability to give informed consent [159]. The exclusion of people with dementia 
because of difficulties with informed consent would leave us with a small, highly 
selected, and non-representative sample of patients left when studying nursing home 
patients. These patients have a lower rate of NPS than patients with dementia [167]. 
Such exclusion would reduce the generalizability to a typical nursing home unit. 
Consent should therefore be given as presumed consent by a relative or legal 
guardian [158]. Given that the rates of dementia in all three cohorts are comparable, 
we do not have reason to believe that patients with dementia were excluded to a 
greater degree in the two latter cohorts.  
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6.3.2 Paper 2 
Internal validity 
The COSMOS study was broad and complex. The design made it possible to adjust 
the intervention to the needs of the participants [15]. This introduces more variability 
and may thereby decrease the internal validity of the results, because the participants 
received somewhat different interventions. However, the method of recruitment and 
data collection was the same across units, thus increasing the internal validity. The 
medication reviews followed the same structure in all units, and we strived to keep 
the given advice and degree of participation consistent. We experienced that the 
physicians and nurses did not have the same needs in the different units, and we saw 
it as necessary to adjust our involvement. Figure 6.3.1 is an outline of the different 
processes in the COMSOS study from Paper 2.  
In hindsight, it would have been favourable to use a more systematic approach to 
assess the implementation process to increase the internal validity of the 
implementation results. Nilsen (2015) [168] described five different categories of 
theories or frameworks that can be used in implementation science. For evaluation of 
implementation, he recommends evaluation frameworks like RE-AIM [169], 
Proctor’s framework [170], or PRECEED-PROCEED [171]. These frameworks 
suggest areas that should be evaluated in implementation studies.  
A recent review aimed at investigating which elements according to the RE-AIM 
framework were important for implementation of psychosocial interventions in 
nursing homes [172]. By looking at what the review found and comparing that to 
what we report, we can consider to which degree we report on implementation 
compared to other studies. The review found that 22% of studies reported reach (the 
proportion of individuals partaking in the intervention), with a variation between 34-
97%. For our study, we met the goal of two staff participating in the intervention per 
unit, giving 100% reach, for the physicians the reach was 33%.  
The review divides effectiveness into knowledge about the intervention and attitudes 
and skills of the staff. The review found that implementation strategies that included 
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training and follow-up, were most successful in improving knowledge, but had 
minimal effect on attitudes or skills. They recommend educational sessions for the 
staff with the addition of follow-up sessions or support of staff. These elements were 
present in the implementation of the COSMOS study. We did not systematically 
assess the staffs’ knowledge about the intervention, and we cannot say whether the 
intervention affected this.  
Adoption was defined as the proportion of caregivers adopting the intervention, and 
was often neglected by the studies in the review. We have no numbers on percentage 
of the staff performing training and medication reviews, but we do know that all 
physicians in our study adopted the intervention. All units logged the intervention, 
and we have a log of the intervention for 92% of the patients.  
Regarding implementation, the RE-AIM review identified factors like percentage of 
perfect delivery, adaptions to the study, costs, and factors affecting implementation. 
On these matters, we reported that 92% of the patients received the medication 
review, and six units received an additional medication review because they felt a 
need for more support to ensure implementation. We also report on barriers against 
and promoters of the implementation.  
The final aspect of the RE-AIM is maintenance. The review points out that there was 
little maintenance of the interventions after six and nine months in the included 
studies. We report data after four months on whether the intervention occurred in the 
first four months. In Paper 3, we also demonstrate how the effects are greatest in the 
first four months. As a note to this, I would like to mention that following the month-
nine data collection, all the participating units were given the initial educational 
programme, where both intervention and control units were invited. Two of the 
municipalities have also invited us to three additional days of courses for the initial 
units and additional units. In one of these municipalities, the council has decided that 
all nursing homes should follow the COSMOS approach, and the other municipality 
is looking into doing the same.  
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The feedback on promoters and barriers was given primarily during the midway 
seminar. Other sources were feedback during the medication reviews and from open-
ended questions in the patient logs. The feedback from the midway seminar was 
given in the same manner from all units. We used a traffic light approach, which is 
widely used in evaluation of teachers and lessons for the units to evaluate the 
intervention. This is not a standard approach for collecting barriers and promoters. 
However this was a part of a process evaluation of the implementation [15] and 
served as a thermometer for challenges and promoters relevant to the trial. It also lead 
to sharing of solutions across units. 
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Figure 6.3.1 The implementation process in the COSMOS study from Paper 2 
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External validity 
The effects we observe in Paper 3 cannot be attributed to the medication review 
alone. The changes may be influenced by the other elements in the study. All the 
patients and relatives, for instance, were invited to have conversations about advance 
care planning. Through these conversations, it is likely that the patients, relatives, and 
staff had a better understanding of the patient’s prognosis and health [173]. A definite 
goal was to increase the quality of life for the patient and offer individualized 
activities for the patients. These factors were involved in the medication reviews and 
may have facilitated deprescribing of preventive drugs. However it is advocated to 
include patient and relatives in discussions about drug use in the patient-centred care 
approach [127]. This increases the external validity by using an already well-known 
method. 
We wanted to measure the degree to which the intervention was implemented and 
what barriers and promoters were involved. The individual adjustments to each 
nursing home reflects how one would have to implement a new procedure in “the real 
world” and increase the external validity. By also assessing adaption of the 
intervention to each nursing home, we increased the transferability of the results to 
other nursing homes by learning from our experiences. 
6.3.3 Paper 3 
Internal validity 
As Paper 2 describes many of the methodological issues of the medication review 
intervention in the COSMOS-study, many of the factors related to validity are 
discussed above. However, some issues have not yet been addressed. Because we 
randomized units rather than physicians, some of the participating physicians worked 
in both intervention and control units. As discussed in the paper, this may mean that 
the interventions of the study bled over to the control groups. If this is the case, the 
differences between control and intervention groups may be underestimated.  
Lack of blinding may lead the nurses to overestimate the effects when scoring the 
patients. The outcomes in this paper use information on prescriptions from the 
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electronic patient records and blood pressure measured by nurses. It might be a 
reasonable to believe that these outcomes are less affected by blinding than more 
subjective measures of improvement, pain, and agitation.  
We used the same assessment scales and procedures on all patients before the 
medication reviews. This ensured that decisions were based on equal grounds. The 
blood pressure, pulse, weight, and height were measured according to local routines. 
We observed a huge variability in these routines. The blood pressures were measured 
with automatic devices, however not repeated three times as recommended [90]. The 
pressures were measured at all times of the day and with the patient either lying or 
sitting. This increases the variability of the measures even further. However, the 
variability should be similar in both groups, and less variability would most likely 
have increased the strength of our findings. It is also important to point out that these 
measures are the ones that the physicians rely on when they evaluate the treatment, 
leading to the discussion of external validity. 
External validity 
In this study, we chose the patients based on the drugs they were prescribed, not 
diagnoses. The drugs all had hypertension as one of their main indications. However, 
there are also many other indications for these drugs, like heart failure or atrial 
fibrillation. The method of selecting patients by drug use has also been used by other 
studies to identify patients with hypertension [174], and the drugs were coded 
according to an international standard to increase transferability [148]. The fact that 
21% of the patients did not have any cardiovascular diagnoses in their medical 
records also underpins the method of using prescriptions, rather than diagnoses, to 
select patients. This is further highlighted by the finding from Paper 1, where there 
was only a small correlation between having a dementia diagnosis on record, and 
having dementia according to CDR [167]. 
The medication review method used in COSMOS was chosen by evaluating the 
studies included in the reviews listed in Table 1.5.3 (we used the 2013 edition of 
Alldred et al. [175]). NPS was assessed in nine of the 39 studies involved in the 
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reviews, and pain in one. Since drugs treating NPS and pain are among the most 
frequently prescribed [5], we wanted to include validated instruments for these 
conditions to be able to evaluate whether the prescribing was appropriate.  
To further evaluate the prescribing, it is necessary to know the patient’s cognitive 
status and level of functioning. High quality of life is a good goal, and a measure of 
this goal was a good starting point for a discussion on what we could do to improve 
the life of this patient. We used a set of validated tools for people with dementia to 
address these symptoms and areas (see section 3.1.1 for a description of the 
instruments), and we used the results actively in the medication review. To our 
knowledge, this is the first study to use this wide and systematic assessment approach 
in medication reviews. 
The nursing home physician is the person responsible for prescribing, and 28% of the 
studies identified by the reviews directly involve the nursing home physician in the 
intervention (these studies are listed in Table 6.2.1) [176-187]. The studies are 
primarily randomized controlled trials involving from 63 to almost 2000 patients in 
nursing homes. Three of the studies also involve the physician in multidisciplinary 
medication reviews. All of these were over 10 years old at the initiation of COSMOS. 
The fact that we included the physician made the intervention closer to day-to-day 
practice and increased external validity.  
Deprescribing is difficult, partly due to professional loneliness and academic 
uncertainty [188]. The COSMOS study introduced a colleague (collegial mentoring) 
to lessen the burden of deprescribing. Visiting colleagues is an accredited part of the 
specialization program for general practitioners in Norway, so the physicians have an 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Prior to the start of the study, the Norwegian Patient Safety Campaign had held an 
extensive campaign advocating medication reviews for the nursing home patients 
[189]. Their method included the use of the START/STOPP criteria, a designated 
checklist of symptoms, suggested lab tests, and a pharmacist visiting the nursing 
home. It was therefore natural to build our method on their approach to increase 
external validity.  
The pharmacist is used in numerous studies to improve or evaluate prescribing (Table 
1.5.3). These studies often show beneficial effects. We also invited the nursing homes 
to include their pharmacist in the medication review. Sadly, none of our nursing 
homes had one available for these sessions.  
The data on drug use were collected at three time points; baseline, month four, and 
month nine. We did not track changes between the data collections. The medication 
reviews were performed in the first two months of the study, giving the physician and 
patient at least two months to evaluate changes after the medication review. During 
this period, the patient could be put back on the drug if the change was not beneficial. 
We therefore believe that the prescriptions we see at month four are the results of true 
changes, rather than unsuccessful pauses. Clinicians testing this intervention might 
therefore experience a lower rate of success – because we did not record the 
“unsuccessful withdrawals”.  
6.4 Discussion of the results 
All the articles show an extensive use of drugs in nursing home patients. The first 
paper found that each average patient uses 6.6 regular drugs; the intervention patients 
in COSMOS used 7.6, and the patients using antihypertensives used on average 9.2 
drugs each. In Paper 1, the patients in the 2011 cohort used more drugs than in the 
2004 and 2009 cohorts, and comparing this with the COSMOS results from 2015–
2016, indicates that drug use is on the rise. In light of the fact that that polypharmacy 
is an individual risk factor for adverse drug events, inappropriate drug use, and falls 
[3], this development cannot be allowed to continue. 
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Psychotropic drugs are an important factor in polypharmacy, and in Paper 1 we found 
73% of the patients use psychotropics. Some patients even use up to seven different 
drugs from this group. Such drugs are important in the treatment of psychosis, 
agitation, depression, and insomnia [69]. However, when we look at the evidence for 
treatment displayed in Table 1.3.1, the effects are minor. A shortcoming with a cross-
sectional study is that we do not know why and for how long these patients had had 
drugs prescribed for them, and we do not know whether there had been any previous 
attempts to deprescribe. A patient expressing severe NPS might have had an 
improvement since the start of the drug, in which using the drug would be 
appropriate. A patient could also have recently started taking a drug, and the effect 
might not have set in yet. On the other hand, patients expressing a low degree of NPS 
may reflect a well-regulated drug regime, or excessive treatment. This raises the 
famous issue of the chicken and the egg: is it the NPS that leads to excessive 
psychotropic prescribing, or is it the excessive psychotropic prescribing that leads to 
NPS.  
To reduce the use of psychotropics, we need to address the NPS. These symptoms 
have multifactorial aetiology [59], which might explain why drugs have so little 
effect in this group of patients. The NPS is both distressing for the patient and the 
caregiver [49], and this might create a call for action, often answered by the 
prescribing of psychotropic drugs [188]. We do not want the patient to suffer, so we 
would rather try a drug than to leave her in distress [188]. This might explain the 
extended use in the patients expressing the most NPS. 
The first step towards management of NPS is a proper assessment of the patient [59]. 
Assessment should include investigating whether the patient is in pain, has an acute 
medical condition, a sensory deficit, or is overstimulated or understimulated. As 
discussed above, it is important to use validated tools when assessing NPS in people 
with dementia. In the studies included in the reviews mentioned in Table 1.5.3, NPS 
is systematically assessed in nine (23%) of the studies and four (10%) have a clinical 
assessment that might include a systematic assessment. However, information on 
whether the information was used in the intervention is lacking. Cognition was 
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assessed in 11 (28%) of the studies, and pain in one (3%). In Paper 2, we found that 
94–97% had dementia, 67% neuropsychiatric symptoms and 52% pain. This 
highlights the necessity of including these assessments when performing a medication 
review both to be able to prescribe correctly, but also to be able to monitor significant 
changes. 
Antihypertensive drugs were used by 50% of the COSMOS patients. High blood 
pressure, defined as systolic pressure ≥140 mmHg was present in 22% of the patients. 
If cut-off is set to ≥160 mmHg, high blood pressure was present in 9% . Tachycardia 
(>100 beats per minute) were present in 7%. These numbers suggest a substantial 
potential for deprescribing.  
If we compare the MMSE scores of the intervention group in Paper 3 with those of 
unselected intervention patients in Paper 2, we see that the distribution is strikingly 
similar, indicating that patients with dementia receive as much antihypertensives as 
patients without dementia. A British epidemiological study of nearly 80 000 
individuals aimed to investigate the outcomes of treating hypertension in people over 
80 years [174]. They excluded patients with comorbidity to investigate the “pure” 
effect of antihypertensive treatment. They found a U-shaped association between 
mortality and systolic pressure, the lowest mortality was between 135–154 mmHg. 
This association remained the same when adjusting or stratifying for pulse-pressure, 
and a range of diseases. It seems that even for the healthiest of the old, a low blood 
pressure is dangerous and the ideal blood pressure is higher than for the young [90]. 
This information should aid deprescribing of antihypertensives in some patients.  
Especially regarding psychotropic drugs, such as antipsychotics, there is increasing 
evidence that drugs can be discontinued without harmful effects to the patient [190]. 
However, there is no single, simple, one-solution-fits-all way of doing this [126], and 
the physician is crucial in this process. At the same time, deprescribing cannot be 
done in a safe and individualized manner without the involvement of the nursing 
staff. They must observe and assess the status of the patient before and after 
deprescribing, and in some cases offer non-pharmacological treatment to avoid 
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deterioration of the patient. Thus, involving both the physician and staff in the 
medication review improves both the clinical effectiveness of the intervention and 
increases patient safety.  
There are many barriers to optimizing prescribing [188, 191]. An interesting result 
from COSMOS is that factors described by some units as barriers are described by 
other units as factors for success. This is also described by Boersma et al. [172]. This 
review identified important factors influencing the implementation of psychosocial 
interventions. The factors identified by most studies were time, support from 
managers, influence of quality of care enthusiastic and experienced team, and the 
conditions. Hence, knowledge about these factors, and cooperating across units, can 
increase success.  
6.5 What does the COSMOS approach add? 
The discussion above has focused on the individual studies and smaller aspects of the 
COSMOS study. There is no question that there are already multiple studies on 
medication reviews and methods to improve prescribing in nursing homes (Table 
1.5.3). To invent a new intervention or test a new method might seem superfluous in  
regard to the variety already tested. However, we felt that there were some aspects 
not thoroughly enough investigated or considered.  
The variety of symptoms 
The patients experience a variety of symptoms [77, 167], and dementia renders the 
patients unable to explain or express these symptoms. Hence, we needed to 
systematically address these symptoms for them.  
Involving the physicians 
It is striking that the physician responsible for the medical treatment of the patients is 
often not directly involved in the studies (Table 6.2.1). In the end,  
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the physicians are the ones prescribing the drugs and the ones in charge of monitoring 
the patients’ health. To ensure a lasting change, the physicians need to be involved in 
the process.  
Identify barriers and promoters 
There is a widespread understanding that polypharmacy is harmful and we should all 
work towards optimal prescribing [9]. Still, the use of drug prescription is increasing 
[4, 78]. To improve prescribing we needed to address some of the barriers to 
deprescribing. Some of these are known from studies [188], and some from our own 
experiences. One particular characteristic of working as a nursing home physician in 
Norway is that one most often works as the only physician in the institution. This is 
contrary to physicians in hospitals experiencing daily contact with colleagues. Having 
support from colleagues can make it easier to make difficult decisions.  
There are also numerous barriers and promoters relevant to changing a practice in an 
institution. We examined these as we conducted the study, and are therefore able to 
tailor the intervention to each nursing home, to increase the possibility of 
implementing the intervention [164].  
 80
7. Conclusion 
The overarching goal of this thesis was to explore how to optimize prescribing for 
two of the major drug groups contributing to polypharmacy, and describe the 
implementation process of the medication reviews in the COSMOS study.  
We found an extensive use of psychotropic drugs, and the use was strongly connected 
to degree of NPS. Antihypertensive drug use was also high, regardless of cognitive 
status. Patients with advanced dementia also had fewer drugs prescribed drugs 
deprescribed.  
Through education and collegial mentoring, all patients in the intervention group 
received medication reviews. Barriers such as of time were reduced and ethical 
dilemmas addressed. The clinical medication reviews reduced the use of preventive 
antihypertensive drugs, without increasing hospitalization or mortality. A decrease in 
these drugs led to an initial increase in blood pressure, however the increase was not 
sustained over time. This demonstrates that the medication review is an ongoing 
process that requires continuous hands-on contact with the patients, their demands, 
wishes and diseases. 
Seeing these results holistically should increase the awareness of drug use in nursing 
home patients. There seems to be an extensive use of drugs, and a great potential for 
deprescribing. To successfully deprescribe, some elements are essential. We need to 
take into account that most patients have dementia, will experience NPS, and that 
pain is very common. Therefore, to evaluate which drugs should receive precedence 
in treatment, these symptoms must be properly assessed as a part of the medication 
reviews.  
By consolidating education, collegial mentoring, and multidisciplinary medication 
reviews, we intended to increase the knowledge of all actors involved in prescribing. 
We discussed the challenging aspects of prescribing together and this facilitated 
discussion on difficult ethical dilemmas. The focus on tracking the effect of drugs, 
and trying to pause drugs, led to a reduction in drug use.  
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8. Implications for further research 
This thesis investigates a small part of prescribing for the nursing home patients. This 
small part has uncovered an extensive use of psychotropics and a substantial nuber of 
neuropsychiatric symptoms. We have also found a method that ensured the patients 
received medication reviews, and decreased the use of preventive drugs. 
This researchs builds on and extends the research at Centre for Elderly and Nursing 
Home Medicine, Department of Global Public Health and Primary Care, University 
of Bergen. This centre aims to conduct research to improve the life of elderly in the 
municipalities, implement research, educate health care professions and the 
community, and collaborate nationally and internationally.  
The next step after this thesis is to investigate how to implement the medication 
reivews in more nursing homes by expanding the project and disseminate it to new 
municipalaties by education collaboration. The research has already been spread and 
implemented in Norway beyond the included nursing homes. The COSMOS 
education program has been optimized and delivered to ten new municipalities. This 
shows how Norwegian nursing homes are focusing on improving care.  
Another question left unaswered is how overall prescribing was affected and which 
drugs were changed the most. Even more importantly – we do not know how the 
patients’ quality of life or symptoms changed throughout the study period. Being a 
complex study, with multiple interventions it is reasonable to believe that it was more 
than the medication reivews that caused changes for the patiets, so these questions 
must be investigated as a whole. 
The intervention took considerable time to implement and investigate and we do not 
know whether it was a cost-effective intervention. One of the more interesting themes 
emerging when visiting different units and analysing the data was the variability 
between units and physichians in prescribing and change. A greater effort should be 
made to investigate these differences.  
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All these papers investigated nursing home patients, however we see an increase in 
home-dwelling elderly. A trial extending this research into the home dwelling has 
partly sprung out of the COSMOS study and will investigate if the intervention can 
translate into home care.  
 
 83
9. Implication for the clinician 
The COSMOS study was a complex study with many moving parts. It took 
considerable effort from the involved parties to attend and for the researchers to 
organize. To translate this into clinical practice, one probably needs a coordinator or 
resource person who can help the units with practical difficulties, finding soulutions 
and gathering the units for problem solving and sharing. This has been solved by 
some of the municipalities involved by reorganizing the tasks for people alredy 
connected to the nursing home management.  
To assess all patients requires a great deal of resources and knowledge. However with 
basic training, most of the staff were able to perform the assessments. And in the 
other end, this increases the speed of the drug review itself, since we aldready had the 
knowledge to evaluate the drugs in question. A reduction in the number of drugs will 
also reduce time spent on preparation and administration of the medication.  
The medication reviews led to improved communication between the physichian and 
nurses, and caused enthusiasm. The use of preventive drugs were also reduced. The 
collegial support lessened the burden of making diffucult decisions alone. In March 
2017, a new regulation from the Norwegian government mandates that every 
physician working in a nursing home is required to have a speciality or be under 
specialization. Clinicians should use this opportunity to visit each other, discuss with 
peers, and focus on what’s right for the patients – not what’s right for one disease at 
the time. This is a part of the specializtion programme and a part of working in a 
demanding enviroment.  
The studies could not have been accomplished without support from the people in the 
nursing home sector. This includes all personnel working with the patients, unit 
managers, nursing home managers, physicians, and key persons in the municipality. 
The involvement of the managers ensured that the personnel had the resources needed 
to carry out the study. The staff in the units did all the extra work concerning data 
collection and implementation. All this extra effort was not funded through the study 
or by the government. This is in contrast with the model for research funding in the 
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hospitals, where funding is received for doing research. It might be time to reconsider 
how research in the municipalities is dependent on the economic resources of the 
individual city.  
Together we can do our best to lessen the burden and end polypharmacy for the 
frailest in our society.  
I will now go back to where I started my story: the nursing homes. My next step will 
be to implement this into my everyday clinical practice, and hopefully be able to 
spread this knowledge to other nursing homes. 
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